Pacific Biosciences Of California (PACB) Share-based Compensation (2010 - 2026)

Pacific Biosciences Of California's Share-based Compensation history runs 17 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 51.54% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $36.9 million (down 39.18% YoY), while the FY2025 annual figure was $41.7 million, down 41.34% from the prior year.
• Share-based Compensation was $4.5 million for Q1 2026 at Pacific Biosciences Of California, down from $9.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $22.7 million in Q1 2022 to a low of $4.5 million in Q1 2026.
• Historically, Share-based Compensation has averaged $15.8 million across 5 years, with a median of $17.9 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation jumped 123.34% in 2022, then sank 52.88% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $18.0 million in 2022, then slipped by 7.64% to $16.6 million in 2023, then dropped by 3.32% to $16.0 million in 2024, then sank by 40.2% to $9.6 million in 2025, then slumped by 53.49% to $4.5 million in 2026.
• The last three Share-based Compensation figures came in at $4.5 million (Q1 2026), $9.6 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.